着床前遺伝子診断（PGD）の世界市場2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Pre-Implantation Genetic Diagnosis (PGD) Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0GIR-00218 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ

• 販売価格（消費税別）

Single User	￥508,080 (USD3,480)	▷ お問い合わせ
Multi User	￥762,120 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,016,160 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、着床前遺伝子診断（PGD）の世界市場を広く調査・分析し、今後の市場展望をまとめております。着床前遺伝子診断（PGD）の種類別市場規模（染色体異常、X連鎖疾患、凍結胚検査、異数性スクリーニング、HLA、その他）、用途別市場規模（幹細胞療法、IVF予後、遅発性遺伝性疾患、遺伝性遺伝性疾患、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、California Pacific Medical Center (CPMC)、Illumina, Inc.、Genea Limited、LabCorp、Quest Diagnostics、IGENOMIX、Cooper Medical, Inc.、Natera, Inc.、Thermo Fisher Scientific Inc.、Reproductive Genetic Innovations、CombiMatrix ・地域別グローバル市場分析 2015年-2020年 ・着床前遺伝子診断（PGD）の北米市場（アメリカ、カナダ、メキシコ） ・着床前遺伝子診断（PGD）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・着床前遺伝子診断（PGD）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・着床前遺伝子診断（PGD）の南米市場（ブラジル、アルゼンチン） ・着床前遺伝子診断（PGD）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：染色体異常、X連鎖疾患、凍結胚検査、異数性スクリーニング、HLA、その他 ・用途別分析：幹細胞療法、IVF予後、遅発性遺伝性疾患、遺伝性遺伝性疾患、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The Pre-Implantation Genetic Diagnosis (PGD) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Pre-Implantation Genetic Diagnosis (PGD) sales will be xx in 2020 from Pre-Implantation Genetic Diagnosis (PGD) million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Pre-Implantation Genetic Diagnosis (PGD) market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Pre-Implantation Genetic Diagnosis (PGD) industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Pre-Implantation Genetic Diagnosis (PGD) and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Pre-Implantation Genetic Diagnosis (PGD) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Pre-Implantation Genetic Diagnosis (PGD) market has been segmented into:
Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA
Others

By Application, Pre-Implantation Genetic Diagnosis (PGD) has been segmented into:
Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Pre-Implantation Genetic Diagnosis (PGD) market presented in the report. This section sheds light on the sales growth of different regional and country-level Pre-Implantation Genetic Diagnosis (PGD) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Pre-Implantation Genetic Diagnosis (PGD) market.

The report offers in-depth assessment of the growth and other aspects of the Pre-Implantation Genetic Diagnosis (PGD) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Pre-Implantation Genetic Diagnosis (PGD) Market Share Analysis
Pre-Implantation Genetic Diagnosis (PGD) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Pre-Implantation Genetic Diagnosis (PGD) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Pre-Implantation Genetic Diagnosis (PGD) sales, revenue and market share for each player covered in this report.

The major players covered in Pre-Implantation Genetic Diagnosis (PGD) are:
Roche
California Pacific Medical Center (CPMC)
Illumina, Inc.
Genea Limited
LabCorp
Quest Diagnostics
IGENOMIX
Cooper Medical, Inc.
Natera, Inc.
Thermo Fisher Scientific Inc.
Reproductive Genetic Innovations
CombiMatrix
Among other players domestic and global, Pre-Implantation Genetic Diagnosis (PGD) market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

レポート目次

---

1 Pre-Implantation Genetic Diagnosis (PGD) Market Overview
1.1 Product Overview and Scope of Pre-Implantation Genetic Diagnosis (PGD)
1.2 Classification of Pre-Implantation Genetic Diagnosis (PGD) by Type
1.2.1 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Type in 2019
1.2.3 Chromosomal Abnormalities
1.2.4 X-linked Diseases
1.2.5 Freeze Embryo Testing
1.2.6 Aneuploidy Screening
1.2.7 HLA
1.2.8 Others
1.3 Global Pre-Implantation Genetic Diagnosis (PGD) Market by Application
1.3.1 Overview: Global Pre-Implantation Genetic Diagnosis (PGD) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Stem Cell Therapy
1.3.3 IVF Prognosis
1.3.4 Late-Onset Genetic Disorders
1.3.5 Inherited Genetic Disease
1.3.6 Others
1.4 Global Pre-Implantation Genetic Diagnosis (PGD) Market by Regions
1.4.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Pre-Implantation Genetic Diagnosis (PGD) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Pre-Implantation Genetic Diagnosis (PGD) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Pre-Implantation Genetic Diagnosis (PGD) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Pre-Implantation Genetic Diagnosis (PGD) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Pre-Implantation Genetic Diagnosis (PGD) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Pre-Implantation Genetic Diagnosis (PGD) Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Pre-Implantation Genetic Diagnosis (PGD) Industry Impact
1.5.1 COVID-19 Potential Implications for the Pre-Implantation Genetic Diagnosis (PGD)
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Pre-Implantation Genetic Diagnosis (PGD)
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.2 California Pacific Medical Center (CPMC)
2.2.1 California Pacific Medical Center (CPMC) Details
2.2.2 California Pacific Medical Center (CPMC) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 California Pacific Medical Center (CPMC) SWOT Analysis
2.2.4 California Pacific Medical Center (CPMC) Product and Services
2.2.5 California Pacific Medical Center (CPMC) Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Illumina, Inc.
2.3.1 Illumina, Inc. Details
2.3.2 Illumina, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Illumina, Inc. SWOT Analysis
2.3.4 Illumina, Inc. Product and Services
2.3.5 Illumina, Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Genea Limited
2.4.1 Genea Limited Details
2.4.2 Genea Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Genea Limited SWOT Analysis
2.4.4 Genea Limited Product and Services
2.4.5 Genea Limited Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.5 LabCorp
2.5.1 LabCorp Details
2.5.2 LabCorp Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 LabCorp SWOT Analysis
2.5.4 LabCorp Product and Services
2.5.5 LabCorp Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.6 Quest Diagnostics
2.6.1 Quest Diagnostics Details
2.6.2 Quest Diagnostics Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Quest Diagnostics SWOT Analysis
2.6.4 Quest Diagnostics Product and Services
2.6.5 Quest Diagnostics Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.7 IGENOMIX
2.7.1 IGENOMIX Details
2.7.2 IGENOMIX Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 IGENOMIX SWOT Analysis
2.7.4 IGENOMIX Product and Services
2.7.5 IGENOMIX Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.8 Cooper Medical, Inc.
2.8.1 Cooper Medical, Inc. Details
2.8.2 Cooper Medical, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Cooper Medical, Inc. SWOT Analysis
2.8.4 Cooper Medical, Inc. Product and Services
2.8.5 Cooper Medical, Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.9 Natera, Inc.
2.9.1 Natera, Inc. Details
2.9.2 Natera, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Natera, Inc. SWOT Analysis
2.9.4 Natera, Inc. Product and Services
2.9.5 Natera, Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.10 Thermo Fisher Scientific Inc.
2.10.1 Thermo Fisher Scientific Inc. Details
2.10.2 Thermo Fisher Scientific Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Thermo Fisher Scientific Inc. SWOT Analysis
2.10.4 Thermo Fisher Scientific Inc. Product and Services
2.10.5 Thermo Fisher Scientific Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.11 Reproductive Genetic Innovations
2.11.1 Reproductive Genetic Innovations Details
2.11.2 Reproductive Genetic Innovations Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Reproductive Genetic Innovations SWOT Analysis
2.11.4 Reproductive Genetic Innovations Product and Services
2.11.5 Reproductive Genetic Innovations Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
2.12 CombiMatrix
2.12.1 CombiMatrix Details
2.12.2 CombiMatrix Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 CombiMatrix SWOT Analysis
2.12.4 CombiMatrix Product and Services
2.12.5 CombiMatrix Pre-Implantation Genetic Diagnosis (PGD) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Pre-Implantation Genetic Diagnosis (PGD) Players Market Share
3.2.2 Top 10 Pre-Implantation Genetic Diagnosis (PGD) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue and Market Share by Regions
4.2 North America Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
4.3 Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
4.5 South America Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
5 North America Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries
5.1 North America Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
5.2 USA Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
5.3 Canada Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
5.4 Mexico Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
6 Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries
6.1 Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
6.2 Germany Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
6.3 UK Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
6.4 France Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
6.5 Russia Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
6.6 Italy Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries
7.1 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
7.2 China Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
7.3 Japan Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
7.4 Korea Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
7.5 India Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
8 South America Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries
8.1 South America Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
8.2 Brazil Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
8.3 Argentina Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Pre-Implantation Genetic Diagnosis (PGD) by Countries
9.1 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
9.3 UAE Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
9.4 Egypt Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
9.5 South Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue and Market Share by Type (2015-2020)
10.2 Global Pre-Implantation Genetic Diagnosis (PGD) Market Forecast by Type (2019-2024)
10.3 Chromosomal Abnormalities Revenue Growth Rate (2015-2025)
10.4 X-linked Diseases Revenue Growth Rate (2015-2025)
10.5 Freeze Embryo Testing Revenue Growth Rate (2015-2025)
10.6 Aneuploidy Screening Revenue Growth Rate (2015-2025)
10.7 HLA Revenue Growth Rate (2015-2025)
10.8 Others Revenue Growth Rate (2015-2025)
11 Global Pre-Implantation Genetic Diagnosis (PGD) Market Segment by Application
11.1 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Application (2015-2020)
11.2 Pre-Implantation Genetic Diagnosis (PGD) Market Forecast by Application (2019-2024)
11.3 Stem Cell Therapy Revenue Growth (2015-2020)
11.4 IVF Prognosis Revenue Growth (2015-2020)
11.5 Late-Onset Genetic Disorders Revenue Growth (2015-2020)
11.6 Inherited Genetic Disease Revenue Growth (2015-2020)
11.7 Others Revenue Growth (2015-2020)
12 Global Pre-Implantation Genetic Diagnosis (PGD) Market Size Forecast (2021-2025)
12.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Size Forecast (2021-2025)
12.2 Global Pre-Implantation Genetic Diagnosis (PGD) Market Forecast by Regions (2021-2025)
12.3 North America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
12.4 Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
12.6 South America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Pre-Implantation Genetic Diagnosis (PGD) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Pre-Implantation Genetic Diagnosis (PGD) Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 8. Roche Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 11. Roche Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. California Pacific Medical Center (CPMC) Corporate Information, Location and Competitors
Table 13. California Pacific Medical Center (CPMC) Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 14. California Pacific Medical Center (CPMC) Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2018-2019)
Table 15. California Pacific Medical Center (CPMC) SWOT Analysis
Table 16. California Pacific Medical Center (CPMC) Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 17. California Pacific Medical Center (CPMC) Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Illumina, Inc. Corporate Information, Location and Competitors
Table 19. Illumina, Inc. Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 20. Illumina, Inc. Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 21. Illumina, Inc. SWOT Analysis
Table 22. Illumina, Inc. Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 23. Illumina, Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Genea Limited Corporate Information, Location and Competitors
Table 25. Genea Limited Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 26. Genea Limited Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 27. Genea Limited SWOT Analysis
Table 28. Genea Limited Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 29. Genea Limited Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. LabCorp Corporate Information, Location and Competitors
Table 31. LabCorp Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 32. LabCorp Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 33. LabCorp SWOT Analysis
Table 34. LabCorp Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 35. LabCorp Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Quest Diagnostics Corporate Information, Location and Competitors
Table 37. Quest Diagnostics Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 38. Quest Diagnostics Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 39. Quest Diagnostics SWOT Analysis
Table 40. Quest Diagnostics Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 41. Quest Diagnostics Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. IGENOMIX Corporate Information, Location and Competitors
Table 43. IGENOMIX Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 44. IGENOMIX Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 45. IGENOMIX SWOT Analysis
Table 46. IGENOMIX Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 47. IGENOMIX Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Cooper Medical, Inc. Corporate Information, Location and Competitors
Table 49. Cooper Medical, Inc. Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 50. Cooper Medical, Inc. Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 51. Cooper Medical, Inc. SWOT Analysis
Table 52. Cooper Medical, Inc. Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 53. Cooper Medical, Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Natera, Inc. Corporate Information, Location and Competitors
Table 55. Natera, Inc. Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 56. Natera, Inc. Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 57. Natera, Inc. SWOT Analysis
Table 58. Natera, Inc. Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 59. Natera, Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Thermo Fisher Scientific Inc. Corporate Information, Location and Competitors
Table 61. Thermo Fisher Scientific Inc. Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 62. Thermo Fisher Scientific Inc. Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 63. Thermo Fisher Scientific Inc. SWOT Analysis
Table 64. Thermo Fisher Scientific Inc. Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 65. Thermo Fisher Scientific Inc. Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Reproductive Genetic Innovations Corporate Information, Location and Competitors
Table 67. Reproductive Genetic Innovations Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 68. Reproductive Genetic Innovations Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 69. Reproductive Genetic Innovations SWOT Analysis
Table 70. Reproductive Genetic Innovations Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 71. Reproductive Genetic Innovations Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. CombiMatrix Corporate Information, Location and Competitors
Table 73. CombiMatrix Pre-Implantation Genetic Diagnosis (PGD) Major Business
Table 74. CombiMatrix Pre-Implantation Genetic Diagnosis (PGD) Total Revenue (USD Million) (2017-2018)
Table 75. CombiMatrix SWOT Analysis
Table 76. CombiMatrix Pre-Implantation Genetic Diagnosis (PGD) Product and Solutions
Table 77. CombiMatrix Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) by Players (2015-2020)
Table 79. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Players (2015-2020)
Table 80. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) by Regions (2015-2020)
Table 81. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Regions (2015-2020)
Table 82. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
Table 83. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Table 84. Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) by Countries (2015-2020)
Table 85. Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) by Countries (2015-2020)
Table 86. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue by Countries (2015-2020)
Table 87. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Table 88. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) by Countries (2015-2020)
Table 89. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Table 90. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) by Type (2015-2020)
Table 91. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Type (2015-2020)
Table 92. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Forecast by Type (2021-2025)
Table 93. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue by Application (2015-2020)
Table 94. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Application (2015-2020)
Table 95. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Forecast by Application (2021-2025)
Table 96. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Pre-Implantation Genetic Diagnosis (PGD) Picture
Figure 2. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Type in 2019
Figure 3. Chromosomal Abnormalities Picture
Figure 4. X-linked Diseases Picture
Figure 5. Freeze Embryo Testing Picture
Figure 6. Aneuploidy Screening Picture
Figure 7. HLA Picture
Figure 8. Others Picture
Figure 9. Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Application in 2019
Figure 10. Stem Cell Therapy Picture
Figure 11. IVF Prognosis Picture
Figure 12. Late-Onset Genetic Disorders Picture
Figure 13. Inherited Genetic Disease Picture
Figure 14. Others Picture
Figure 15. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share in 2019
Figure 24. Global Top 10 Players Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Regions (2015-2020)
Figure 28. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Regions in 2018
Figure 29. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 30. Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 32. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 34. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Figure 35. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries in 2019
Figure 36. USA Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 37. Canada Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 39. Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries in 2019
Figure 41. Germany Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 42. UK Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 43. France Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 44. Russia Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 45. Italy Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries in 2019
Figure 48. China Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 49. Japan Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 50. Korea Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 51. India Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 53. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Figure 54. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries in 2019
Figure 55. Brazil Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 60. UAE Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue and Growth Rate (2015-2020)
Figure 63. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Type (2015-2020)
Figure 64. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Type in 2019
Figure 65. Global Pre-Implantation Genetic Diagnosis (PGD) Market Share Forecast by Type (2021-2025)
Figure 66. Global Chromosomal Abnormalities Revenue Growth Rate (2015-2020)
Figure 67. Global X-linked Diseases Revenue Growth Rate (2015-2020)
Figure 68. Global Freeze Embryo Testing Revenue Growth Rate (2015-2020)
Figure 69. Global Aneuploidy Screening Revenue Growth Rate (2015-2020)
Figure 70. Global HLA Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Application (2015-2020)
Figure 73. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Share by Application in 2019
Figure 74. Global Pre-Implantation Genetic Diagnosis (PGD) Market Share Forecast by Application (2021-2025)
Figure 75. Global Stem Cell Therapy Revenue Growth Rate (2015-2020)
Figure 76. Global IVF Prognosis Revenue Growth Rate (2015-2020)
Figure 77. Global Late-Onset Genetic Disorders Revenue Growth Rate (2015-2020)
Figure 78. Global Inherited Genetic Disease Revenue Growth Rate (2015-2020)
Figure 79. Global Others Revenue Growth Rate (2015-2020)
Figure 80. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
Figure 84. Europe Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
Figure 86. South America Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel

---